Twist Bioscience Co. (NASDAQ:TWST) SVP Sells $33,788.30 in Stock

Twist Bioscience Co. (NASDAQ:TWST) SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $33,788.30. Following the transaction, the senior vice president now directly owns 91,511 shares in the company, valued at approximately $3,397,803.43. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Paula Green also recently made the following trade(s):

• On Tuesday, April 2nd, Paula Green sold 229 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total transaction of $7,497.46.
• On Wednesday, March 20th, Paula Green sold 200 shares of Twist Bioscience stock. The stock was sold at an average price of $33.52, for a total transaction of $6,704.00.
• On Wednesday, March 6th, Paula Green sold 600 shares of Twist Bioscience stock. The shares were sold at an average price of $37.43, for a total transaction of $22,458.00.

Twist Bioscience Price Performance

Shares of Twist Bioscience stock opened at $43.13 on Wednesday. The business has a 50 day moving average price of $34.15 and a 200 day moving average price of $31.52. The company has a market capitalization of $2.51 billion, a P/E ratio of -12.84 and a beta of 1.64. Twist Bioscience Co. has a 1 year low of $11.81 and a 1 year high of $44.92.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The business had revenue of $75.30 million for the quarter, compared to the consensus estimate of $70.70 million. During the same period in the prior year, the business earned ($1.06) earnings per share. The business’s revenue was up 25.1% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Co. will post -3.17 EPS for the current fiscal year.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Twist Bioscience by 23.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,617 shares of the company’s stock valued at $316,000 after acquiring an additional 2,933 shares during the last quarter. Strs Ohio grew its holdings in Twist Bioscience by 6.5% in the third quarter. Strs Ohio now owns 27,900 shares of the company’s stock valued at $565,000 after purchasing an additional 1,700 shares during the period. Rockland Trust Co. increased its holdings in shares of Twist Bioscience by 29.7% during the 3rd quarter. Rockland Trust Co. now owns 38,500 shares of the company’s stock worth $780,000 after buying an additional 8,808 shares during the last quarter. TD Asset Management Inc raised its holdings in shares of Twist Bioscience by 137.7% in the 3rd quarter. TD Asset Management Inc now owns 73,148 shares of the company’s stock worth $1,482,000 after purchasing an additional 42,374 shares during the period. Finally, Allspring Global Investments Holdings LLC lifted its holdings in shares of Twist Bioscience by 51.8% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after acquiring an additional 1,179 shares in the last quarter.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Evercore ISI increased their price objective on Twist Bioscience from $46.00 to $50.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Barclays upped their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Robert W. Baird boosted their price target on Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and raised their price objective for the company from $25.00 to $45.00 in a research note on Wednesday, January 17th. Finally, Scotiabank upped their target price on Twist Bioscience from $43.00 to $48.00 and gave the company a “sector outperform” rating in a report on Monday. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $42.50.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.